Panic disorder is an anxiety disorder that can be treated by long-term administration of tricyclic antidepressants such as imipramine, monoamine oxidase inhibitors such as phenelzine, or the selective serotonin reuptake inhibitor (SSRI) antidepressants. Clinical data also indicate that some benzodiazepines, such as alprazolam, are effective antipanic agents, and that their therapeutic onset is faster than that of antidepressants. Benzodiazepines are well known for their action at GABA A receptors, and preclinical data indicate that imipramine and phenelzine also interfere with the GABAergic system. In addition some clinical data lend support to decreased benzodiazepine-sensitive receptor function in panic disorder patients. Using imipramine, phenelzine and alprazolam, we investigated, in rats, the possibility that the therapeutic efficacy of antipanic agents stems from the remodeling of GABAergic transmission in the pons-medulla region. Of the 12 GABA A receptor subunit (␣1-6, ␤1-3, ␥1-3) steady-state mRNA levels investigated, we observed an increase in the levels of the ␣3-, ␤1-and ␥2-subunit transcripts with all three antipanic agents tested. The effects of imipramine and phenelzine on these subunits occurred after 21 days of treatment, while alprazolam effects were observed after 3 days of administration. Histochemical data suggest that the ␣3␤1␥2 subunits comprise a receptor subtype in the pons-medulla region. Therefore, we conclude that these molecular events parallel the therapeutic profile of the drugs examined. We further propose that these events may correspond to a remodeling of the GABA A receptor population, and may be useful markers for investigation of the antipanic properties of drugs. Molecular Psychiatry (2001) 6, 404-412.
Introduction
Anxiety disorders are among the most common psychiatric illnesses, and panic disorder (PD) has a lifetime prevalence of 1.2-3% in the general population. 1 This disorder is characterized by the recurrence of panic attacks which are episodes of intense fright accompanied by the fear of dying, losing control or losing one's mind. Epidemiological studies have indicated that PD runs in families and that female patients are twice as numerous as males. 1 In laboratory models the brainstem has been repeatedly implicated in the pathophysiology of PD. Indeed, the range of somatic symptoms occurring during laboratory-induced and naturally-occurring panic attacks suggest hyperactivity of the autonomic nervous system in PD. 2, 3 Clinical studies looking at brainstem-evoked further supported a role for the brainstem in PD. The main brainstem areas suspected to be involved in PD are the nucleus tractus solitarius, the locus coeruleus and the periaqueductal gray which are highly interconnected and are also linked to the medullary cardiovascular and respiratory centers. 3 Thus, activation of any of these nuclei may be responsible for the somatic symptoms associated with panic attacks.
Evidence for a role of noradrenaline or serotonin in PD has been reviewed extensively by several authors. [6] [7] [8] The noradrenaline and serotonin transmitter hypotheses provide explanations for the efficacy of antidepressants, however, antipanic treatment with antidepressants is characterized by an initial worsening of the symptoms, 9 and requires long-term drug administration to achieve clinical improvement. 10 This initial exacerbation of symptoms, in a time frame which corresponds to the rapid elevation in brain monoamine levels, contrasts to what would be expected if abnormalities in the monoaminergic systems were primarily involved in the pathophysiology of PD. The delayed onset of therapeutic action of these antidepressant/ antipanic drugs suggests that it may be a consequence of neurotransmission remodeling.
Alterations in the GABAergic system may offer an alternate hypothesis to explain the pathophysiology of PD. Imipramine, a tricyclic antidepressant with antipanic properties, increases GABA release from the rat thalamus. 11 Phenelzine, an antidepressant monoamine oxidase inhibitor also prescribed as an antipanic agent, elevates CNS GABA levels, 12, 13 an effect attributable, at least in part, to GABA transaminase inhibition. [13] [14] [15] Alprazolam and clonazepam are the two benzodiazepines most frequently prescribed 10, 16, 17 for PD; like other benzodiazepines they are positive modulators of the GABA A receptors through their interaction at specific allosteric recognition sites. 18 Evidence supports a decreased benzodiazepinesensitive receptor function in anxious patients, 19, 20 but studies investigating benzodiazepine binding in PD patients concentrated on cortical areas and did not examine the receptor density in the brainstem, probably due to issues of resolution. [21] [22] [23] [24] Compared to healthy volunteers, pre-or post-treatment plasma or cerebrospinal fluid GABA concentrations are not significantly altered in PD patients, [25] [26] [27] although Rímon et al 25 found that low pretreatment levels of cerebrospinal fluid GABA correlated significantly with poor therapeutic outcome.
GABA A receptors are formed by five subunits arranged around a Cl − ion channel. The heterogeneity of GABA A receptors has been revealed by the identification of numerous subunit isoforms (to date: 6␣, 3␤, 3␥, 1␦, 3, 1, 1⑀ and 1), generating a potentially huge variety of GABA A receptors. 18, 28 The GABA A receptor has a rich pharmacology, with a number of binding sites for therapeutically useful agents, such as benzodiazepines, barbiturates and some anesthetics, that are allosterically linked to the GABA-agonist site. The pharmacological profile of a GABA A receptor subtype is exquisitely determined by its particular subunit composition. 18, [28] [29] [30] [31] Many studies have demonstrated that chronic treatment with agonists or allosteric modulators of the GABA A receptor produces specific changes in receptor characteristics and subunit gene expression. 28 We tested the hypothesis that antipanic agents may exert their therapeutic effect by remodeling GABAergic transmission in the pons-medulla region. The number of possible subunit isoform combinations exceeds by far the number of GABA A receptor subtypes that have been identified either pharmacologically or electrophysiologically. However, there is a good correlation between GABA A receptor subunit mRNA and protein levels, [32] [33] [34] suggesting that changes in specific mRNA levels are likely to reflect changes in the amount of protein present, and by extrapolation, possible changes in the subunit composition of the GABA A receptor subtype expressed, as has been shown by a number of other studies. 35, 36 Hence, steady-state mRNA levels of 12 GABA A receptor subunits were measured in rat brainstem after 3 or 21 days of treatment with three commonly used antipanic drugs with known effects on
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GABAergic systems: the tricyclic antidepressant imipramine, the monoamine oxidase inhibitor phenelzine, and the benzodiazepine alprazolam. We included in this study the anxiolytic buspirone as a negative control, as it is an anxiolytic that acts via presynaptic 5-HT 1A receptors, requires chronic administration for its therapeutic effect, but is not an antipanic agent. A preliminary report of this work has been published 37 in which only the three major GABA A receptor subunit mRNAs, encoding the ␣1-, ␤2-and ␥2-subunits, were examined in the same set of animals but with no replication of mRNA level determination.
Material and methods

Chronic administration of drugs
All animal procedures were approved by the Health Sciences Animal Welfare Committee (University of Alberta, Canada) and conducted according to the guidelines of the Canadian Council on Animal Care. Drug delivery was achieved as described previously 37 using Alzet (Palo Alto, CA, USA) osmotic minipumps to deliver either phenelzine at 15 mg kg −1 day −1 (n = 6), imipramine at 20 mg kg −1 day −1 (n = 6), buspirone at 4 mg kg −1 day −1 (n = 6), alprazolam at 10 mg kg
(n = 6) or the corresponding vehicles (distilled water for buspirone, imipramine and phenelzine, and dimethylsulfoxide: propylene glycol, 50:50 (v/v) for alprazolam). Surgical implantation into male SpragueDawley rats weighing initially between 175 and 200 g was conducted under methoxyflurane inhalation anesthesia. After the treatment period the animals were decapitated without anesthesia to avoid interference of the anesthetic with GABAergic transmission. 38 The brains were immediately dissected on ice, and the tissue samples were frozen individually in microfuge tubes placed in a dry-ice ethanol bath. Liver and spinal cord samples were taken from each of the 21-day treated animals and frozen on dry ice for the assessment of drug delivery by the determination of drug levels, as previously described. 37, 39 Total RNA was isolated from each brain tissue sample using Trizolreagent (Gibco-BRL, Burlington, ON, Canada) and stored at −80°C under ethanol.
Determination of steady-state mRNA levels
A modified version of the multiprobe solution hybridization assay was used for the quantification of GABA A receptor subunit steady-state mRNA levels as we have described 40 and used in similar experiments 37, 41, 42 previously, using antisense oligonucleotides to published rat sequences. 37 Autoradiographic images were captured on a flat-bed scanner 42 and analyzed with NIH Image v1.56 (Wayne Rasband, RSB, NIMH, NIH, Bethesda, MD, USA) as we have described previously. 37, 41, 42 Briefly, band intensities were converted to optical densities by the use of a Kodak gray scale calibration step tablet. Optical density plots of each electrophoresis lane were determined and the area under the curve was integrated for each peak and normalized to that of the internal standard present in Levels of imipramine, and its primary active metabolite, desipramine were determined in spinal cord after 3 and 21 days of treatment. Alprazolam and buspirone levels were on the limit of detection in spinal cord and were therefore determined in liver. Data represent the mean ± SEM (n = 6).
the same lane. Data points outside the linear range of the detection system were excluded. The normalized value of each oligonucleotide band was expressed as a percentage of the mean normalized value of the vehicle-treated group. Pooled data sets were obtained for each mRNA species by performing 2-5 replicate multiprobe solution hybridizations with each oligonucleotide probe.
Statistical analyses
Results from each individual animal were expressed as a percentage of the corresponding vehicle mean. Consequently, all the vehicle group mean values equated to 100%, allowing their combination and the pairwise comparison of each treatment group to the compiled vehicle group using Dunnett's test (Software GB-Stat PPC v6.5.2). Mean ± SEM vehicle mRNA levels and significant F ratios from individual subunit oneway ANOVA are indicated in the text. The statistical significance was established using the general convention of P Ͻ 0.05.
Results
Assessment of drug delivery after 3 and 21 days of treatment demonstrated that the vehicles used were appropriate for allowing both short-and long-term delivery via osmotic minipumps and that appropriate drug levels were achieved in all animals (Tables 1  and 2 ). Spinal cord GABA levels were determined after 3 and 21 days of phenelzine treatment and expressed as percentage of levels determined in vehicle control animals. Similarly, monoamine oxidase A and B activities were determined and expressed as percentage inhibition compared to vehicle control animals. Data represent the mean ± SEM (n = 6).
The initial experiments examined the effects of a 21-day drug treatment on all GABA A receptor subunit mRNA levels on the basis that this corresponds to a treatment time equivalent to that required to produce a therapeutic effect in the clinical setting. Many significant changes in ␣-subunit mRNA levels were found (Figure 1) , mostly in the imipramine-treated animals where ␣1-, ␣4-, ␣5-and ␣6-subunit mRNA levels were significantly increased by 57, 80, 108 and 238%, respectively (Vehicle ␣1 = 100 ± 9%, F ␣1 (4, 34) = 7.203, P Ͻ 0.05; Vehicle ␣4 = 99 ± 10%, F ␣4 (4, 34) = 5.557, P Ͻ 0.05; Vehicle ␣5 = 100 ± 6%, F ␣5 (4, 34) = 15.918, P Ͻ 0.05; Vehicle ␣6 = 101 ± 21%, F ␣6 (4, 33) = 4.008, P Ͻ 0.05). Alprazolam significantly increased the level of expression of the ␣2-subunit gene (76%), whereas buspirone significantly decreased the level of this mRNA by 47% (Vehicle ␣2 = 101 ± 7%, F ␣2 (4, 34) = 3.1, P Ͻ 0.05). No effect on ␣-subunit mRNA levels were produced by phenelzine. Changes in the expression of ␤-subunit genes after chronic antipanic drug administration are shown in Figure 2 . Imipramine increased the levels of all three ␤-subunit transcripts (␤1 by 53%, ␤2 by 26% and ␤3 by 39%), whereas phenelzine only increased ␤1-subunit mRNA levels (66%) (Vehicle ␤1 = 101 ± 9%, F ␤1 (4, 34) = 4.381, P Ͻ 0.05; Vehicle ␤2 = 101 ± 5%, F ␤2 (4, 34) = 13.858, P Ͻ 0.05; Vehicle ␤3 = 100 ± 5%, F ␤3 (4, 34) = 8.809, P Ͻ 0.05). Alprazolam decreased the levels of ␤2-subunit mRNA by 24% and buspirone decreased ␤2-and ␤3-subunit mRNA levels (34 and 29%, respectively). Further, it should be noted ( Figure 2 ) that all the antipanic drugs displayed an opposite effect to buspirone on the expression of the ␤1-subunit gene although alprazolam-induced changes did not reach significance. The antipanic agents also had opposite actions on the expression of the ␤3-subunit gene to buspirone, but imipramine was the only drug to produce a significant effect. Similar to the changes in gene expression of the ␣-and ␤-subunit genes, the pattern of alterations in ␥-subunit mRNA levels were drug-specific (Figure 3) . Imipramine significantly increased the expression of the ␥2-and ␥3-subunit genes by 81% and 114%, respectively. Phenelzine increased ␥2-subunit mRNA levels by 52%, while buspirone and alprazolam did not produce any significant effects (Vehicle ␥2 = 101 ± 6%, F ␥2 (4, 34) = 11.224, P Ͻ 0.05; Vehicle ␥3 95 ± 11%, F ␥3 (4, 33) = 4.779, P Ͻ 0.05). In general, all the antipanic agents increased the expression of the ␥2-subunit gene, which was in contrast to buspirone, but the 33% increase produced by alprazolam was smaller than that of imipramine and phenelzine and did not reach significance. Another common effect of the antipanic drugs on ␥1-subunit mRNA seemed to emerge, but again significance was not reached.
Although the results described above did not reveal a common significant effect of all three antipanic drugs, one of our aims was to identify trends across the antipanic drug group. As such, the ␣3-, ␤1-and ␥2-subunit genes provided a possible common target for antipanic drug action as their expression was increased following the 21-day treatment period. This pattern of effects GABA A receptor ligands induce differential timedependent changes in the expression of these receptor subunit genes. 41, [43] [44] [45] In addition, the onset of benzodiazepine antipanic therapy seems faster than that of the antidepressants.
9,10,46-49 Consequently, the therapeutic approach is often to start patients with co-treatment of a benzodiazepine and an antidepressant, and to gradually taper the benzodiazepine after the onset of the therapeutic effect. 49, 50 While the present study was underway, we found in a separate series of experiments, that chronic treatment with various benzodiazepine-site ligands produces transient changes in GABA A receptor mRNA levels. 41 This finding suggests the possibility that alprazolam causes its effects on GABA A receptor gene expression at an earlier time period than 21 days in a similarly transient manner. We therefore examined the effects of these drugs on the expression of the candidate GABA A receptor ␣3-, ␤1-and ␥2-subunit genes following a short-term treatment of 3 days (Figure 4) . Alprazolam significantly increased ␣3-, ␤1-and ␥2-subunit gene expression by 32%, 72% and 143% respectively, whereas imipramine, phenel- Figure 4 Effect of short-term (3 days) drug treatment on GABA A receptor ␣3-, ␤1-and ␥2-subunit mRNA levels in brainstem. Data represent the mean ± SEM (n = 6) percentage change in ␣3-, ␤1-and ␥2-subunit transcript abundance relative to the vehicle-treated group. Statistical analyses were performed by the Dunnett's test pairwise comparison between drug-and vehicle-treated groups, *P Ͻ 0.05. zine and buspirone were devoid of any significant effects (Vehicle ␣3 = 98 ± 4%, F ␣3 (4, 31) = 4.582, P Ͻ 0.05; Vehicle ␤1 = 98 ± 8%, F ␤1 (4, 30) = 7.652, P Ͻ 0.05; Vehicle ␥2 = 92 ± 9%, F ␥2 (4, 31) = 4.601, P Ͻ 0.05).
Discussion
We have previously shown that the antipanic agents used here alter the expression of GABA A receptor subunit genes in brainstem. 37 That study failed to find a common effect of antipanic drug exposure but was limited to an analysis of the ␣1-, ␤2-and ␥2-subunit genes, which are the major GABA A receptor subunit genes in mammalian brain. In the current work we have extended those preliminary findings by examining all known ␣-, ␤-and ␥-subunit genes. Our main conclusion is that imipramine and phenelzine increase ␣3-, ␤1-and ␥2-subunit gene expression after 21 days while alprazolam administration has the same consequence after 3 days of drug exposure. These effects are consistent with the therapeutic efficacy time-lines of the respective antipanic agents. Importantly, we found that the anxiolytic buspirone, which is deficient in antipanic efficacy, had no such effect.
Two differences were found in the present data set compared to that previously described by us for the ␣1-, ␤2-and ␥2-subunit genes 37 which can be accounted for by methodological differences. The first is that the amplitude of increase in ␣1-subunit mRNA level by imipramine reported here (57%) is lower than that of the previous data set (178%), but both are significantly different from their respective controls. The second and main difference between the two sets of results lies in the effect of 21-day alprazolam treatment on ␥2-subunit mRNA levels. Here we show a non-significant 33% increase whereas we previously found a significant decrease of 44%. 37 Although we used six animals per group previously, the data we reported were derived from single determinations of steadystate mRNA levels in each animal whereas the current work represents the pooled results of 2-5 replicate determinations (mostly 3-4). The decision to replicate the experiments stemmed from our empirical observation that the multiprobe solution hybridization method presented a degree of inter-experiment variation, the origins of which remain unknown. For this data set, the overall inter-experiment variation for each treatment × subunit data was such that three out of four replicate means are in the range of ± 40.62% of the pooled mean. We also found that capturing the autoradiographic images using a flat-bed scanner rather than by video camera reduced inter-run variations (data not shown). Finally, the present data were analyzed using Dunnett's pairwise comparison as opposed to Fisher's least significance difference as the post-ANOVA test. We feel that this is a more appropriate statistical approach for two reasons. First, Dunnett's pairwise comparison is a more conservative test. Second, the hypothesis it tests (Are any of the treatment groups different to the control group?) matches our line of investigation (Are there any common effects of the antipanic agents?). Indeed, renalysis of the previous data set 41 with Dunnett's pairwise comparison indicates that the 44% decrease in ␥2-subunit mRNA levels caused by 21-day alprazolam treatment is not significant. The above methodological differences Molecular Psychiatry apply to all the data presented here. One other fact that is specific for the 21-day alprazolam group is that the data presented here derive from a different set of animals to that used previously. This was necessitated after finding that mRNA degradation had occurred in the original samples. The spinal cord drug concentration of the first group was also more heterogeneous (37.44 ± 16.25 ng g −1 ranging from 2.40 to 103.15 ng g −1 ) than that of the second (23.37 ± 3.87 ng g −1 with a range from 9.08 to 38.01 ng g
−1
). We therefore believe that the small differences in mean mRNA levels between the two data sets do not detract from the main findings of this work.
We showed that the drugs used in this study were effectively delivered by the osmotic minipumps; while we feel that such confirmation is important, it is usually not done in other such studies reported in the literature. Although the doses for the different drugs were chosen to produce brain concentrations similar to those measured in patients, 11 we cannot be certain that these doses are pharmacologically identical. Consequently, while we demonstrated appropriate drug delivery we did not necessarily expect quantitatively similar effects. Another important aspect of the current investigation is the inclusion of buspirone, which is used in the treatment of anxiety disorders but does not have therapeutic efficacy in PD, enabling us to look for qualitative effects that were shared only by the antipanic drug group.
The search for a common effect of the antipanic agents among the drug-specific patterns of gene expression thus began with the observation that for the time points investigated, buspirone never significantly increased the expression of any receptor subunit genes. In contrast, the antipanic drugs increased the levels of ␣3-, ␤1-and ␥2-subunit steady-state mRNA after 3 days (alprazolam) or 21 days (imipramine, phenelzine) of treatment. The increase in ␣3-subunit mRNA levels induced by alprazolam treatment (32%) is comparable to the positive effects of imipramine and phenelzine (18% and 27%, respectively). Similarly, the expression of the ␤1-subunit gene was increased following alprazolam, imipramine and phenelzine treatments (by 72%, 53% and 66%, respectively). Finally, if an outlying value within the group treated with alprazolam for 3 days (511% of control, but which still lies within two standard deviations of the mean) is excluded, the mean increase in ␥2-subunit mRNA levels becomes 70% (from 143%), which falls between the mean increases induced by treatment with imipramine and phenelzine for 21 days (81% and 52%, respectively). Thus, in contrast to buspirone, the three antipanic agents tested increased ␣3-, ␤1-, and ␥2-subunit gene expression in the brainstem. Importantly, however, these drug-specific effects occurred on a different time scale.
Numerous clinical reports indicate that several weeks of administration are required for the onset of the antipanic effect of imipramine and phenelzine, 9, 10, 17 whereas the antipanic action of benzodiazepines becomes apparent after one week of treatment. 9, 10, [46] [47] [48] [49] Hence, 21 days of treatment is probably optimal for the observation of GABA A receptor gene expression changes induced by imipramine and phenelzine, while 3 days of administration may be more relevant to investigate the alterations produced by alprazolam. Indeed, chronobiological studies of the effects of other benzodiazepine site ligands on GABA A receptor subunit gene expression carried out by members of our group revealed that maximal changes in subunit mRNA levels were observed after 7 or 14 days of treatment, 41, 44 often returning to baseline values following longer treatment periods (unpublished). The present data are consistent with these reports since the increase observed after 3 days of alprazolam treatment on ␣3-, ␤1-and ␥2-subunit mRNA levels waned after 14 (data not shown) and 21 days of treatment, while chronic administration was required for imipramine and phenelzine to produce this effect. This suggests that alprazolam produces its effects by direct modulation of GABA A receptor activity whereas imipramine and phenelzine most likely produce their effects on GABA A receptor expression via an indirect route, perhaps by initially modulating non-GABAergic pathways.
Since the drugs' maximal effects on ␣3-, ␤1-and ␥2-subunit mRNA levels parallel the time-scale of their respective therapeutic onsets, it is therefore possible that the changes in GABA A receptor subunit gene expression reported here may be concomitant or subsequent to their antipanic efficacy. Gene expression can be regulated at the level of both mRNA and protein.
Consequently, the short-term changes in mRNA levels produced by alprazolam may presage a long-term effect on protein levels produced by subsequent changes in the rate of protein synthesis or degradation.
The common effect of the three antipanic drugs on GABA A receptor ␣3-, ␤1-and ␥2-subunit mRNA levels could be interpreted as preceding an increase in the number of ␣3␤1␥2 GABA A receptors, or alternatively as reflecting a positive feedback mechanism to an increased degradation of the corresponding proteins. Evidence suggests that this receptor subtype may occur naturally in the brainstem. The ␣3 subunit is widely distributed throughout the brainstem, and this subunit's mRNA is found in the nucleus tractus solitarius, the gigantocellular nuclei, the reticular formation and the laterodorsal tegmental nuclei. 51, 52 In contrast, although the ␥2 subunit is the most abundant and widely distributed ␥ subunit in the brain, the distribution of this subunit is not ubiquitous in the brainstem. The ␥2-subunit mRNA is present in the reticular formation, the gigantocellular, the pontine, the parabrachial and raphé nuclei, but not the nucleus tractus solitarius and the locus coeruleus. [52] [53] [54] Similarly, the distribution of the ␤1-subunit mRNA is restricted to discrete areas of the brainstem such as the locus coeruleus, the nucleus tractus solitarius, and the raphé, pontine, parabrachial and gigantocellular nuclei. [52] [53] [54] Taken together, these in situ hybridization studies suggest that ␣3-, ␤1-and ␥2-subunit mRNAs co-localize in the tegmental, parabrachial and gigantocellular nuclei neurons.
Immunohistochemical studies with ␣3-and ␥2-subunit-specific antibodies have, however, revealed the presence of the ␣3␥2 subunit combination in the reticular formation, auditory pathway, locus coeruleus, nucleus tractus solitarius, and raphé. 32 Hence, some of these nuclei, such as the nucleus tractus solitarius and locus coeruleus, are immunopositive for a subunit (␥2) but do not contain the corresponding mRNA. Such a discrepancy between the protein and the mRNA levels may be explained by differences in the sensitivity of the detection methods (normally a one-to-one detection for in situ mRNA hybridization vs amplification with secondary or tertiary antibodies for immunocytochemistry), by an mRNA and its cognate protein having widely different half lives, or by afferent projections from neuronal cell bodies located in different brain structures expressing the corresponding gene, that project onto the neuron cell bodies which do not contain the particular subunit. The increases in ␣3-, ␤1-and ␥2-subunit mRNAs we report here may be located in the tegmental, parabrachial and gigantocellular nuclei where these subunits colocalize, but the functional changes might be expected, for example, in the locus coeruleus to which the gigantocellular nuclei neurons project.
An alteration in the level of the ␣3␤1␥2 GABA A receptor subtype may correspond either to a change in the total number of GABA A receptors or a switch within the receptor subtype population, either of which would be expected to alter GABAergic tone at a particular synapse. Indeed, previous data have indicated that ␣3␤1␥2 receptors display lower GABA-gated maximal current amplitudes and higher GABA EC 50 values compared to many other receptor subtypes. [55] [56] [57] [58] [59] [60] Hence, the substitution of a given receptor subtype for the ␣3␤1␥2 subunit combination may decrease GABAergic inhibition, while a change in the total number of GABA A receptors would alter GABAergic tone at a particular synapse in a similar manner.
According to Ballenger, 9 the long-term pharmacological treatment of PD includes three phases: acute, stabilization and maintenance. In this model, the acute phase corresponds to the onset of the antipanic effect (reduction of symptoms) while the stabilization and the maintenance phases aim at the maintenance of the improvement and the extension of the therapeutic effect to other aspects of the disorder, such as anticipatory anxiety and phobic avoidance. Hence, the establishment of a correlation between the changes in ␣3-, ␤1-and ␥2-subunit transcript levels and the therapeutic onset of antipanic drugs would be in accordance with this model, and provide a molecular basis for the earlier onset of action of alprazolam. 9 To summarize, among all the GABA A receptor subunit genes whose expression was investigated, alterations in the ␣3-, ␤1-and ␥2-subunit mRNAs are the best candidates for being the molecules commonly affected by antipanic drugs. Indeed, the upregulation of ␣3-, ␤1-and ␥2-subunit transcripts after chronic treatment with antipanic drugs may correspond to a remodeling of the receptor subunit composition within particular brainstem nuclei and receptors. Such subunit substitution is expected to alter the inhibitory effects of GABA on the targeted receptors and the GABAergic regulatory tone on a particular brain structure. Finally, these alterations in GABA A receptor subunit gene expression may be useful as molecular markers for screening potential antipanic agents. In recent years the SSRI antidepressants have come to be used frequently as antipanic agents, and we are now extending these studies on GABA A receptor subunit gene expression to these drugs.
